Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Rhea-AI Summary
Liminatus Pharma (Nasdaq: LIMN) announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The move enables LIMN shares to continue trading on Nasdaq under the existing ticker.
The Nasdaq Hearings Panel granted Liminatus an extension until September 3, 2026 to regain compliance with Nasdaq’s minimum bid price requirement. The company intends to take necessary actions within this period, and its stock will continue trading on the Nasdaq Capital Market, subject to ongoing compliance with the Panel’s decision and other Nasdaq continued listing standards.
Positive
- Extension to regain bid price compliance until September 3, 2026
- Shares continue trading on Nasdaq Capital Market under ticker LIMN
- Regained time window supports ongoing corporate and clinical development plans
Negative
- Transfer from Nasdaq Global Market to Capital Market reflects non-compliance status
- Company remains out of compliance with minimum bid price requirement
- Continued listing depends on meeting Panel conditions by September 3, 2026
Market Reaction – LIMN
Following this news, LIMN has gained 10.51%, reflecting a significant positive market reaction. Argus tracked a peak move of +41.7% during the session. Our momentum scanner has triggered 64 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $0.12. Trading volume is exceptionally heavy at 10.6x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | merger amendment | Positive | +4.0% | Merger terms were amended to facilitate closing before stockholder approval. |
| Jun 03 | warrant exercise | Negative | -22.2% | Investors exercised existing warrants while receiving new warrants at a lower exercise price. |
| May 21 | delisting notification | Negative | -31.1% | Nasdaq issued a delisting notice citing market value listing deficiencies. |
| May 21 | merger agreement | Positive | +31.0% | Liminatus signed a definitive agreement to acquire InnocsAI. |
| Mar 17 | clinical trial plan | Neutral | -2.5% | The company announced plans to initiate a Phase 1 trial for IBA101. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions generally aligned with the apparent sentiment of corporate and listing-related announcements, while the planned clinical-trial announcement diverged.
Key Terms
nasdaq capital market regulatory
nasdaq hearings panel regulatory
minimum bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement.
The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, “LIMN.” The Nasdaq Capital Market is one of Nasdaq’s three listing tiers.
In addition, the Panel has granted the Company’s request for an extension to demonstrate compliance with the applicable minimum bid price requirement. Under the Panel’s decision, the Company has until September 3, 2026 to demonstrate compliance with the Bid Price Rule.
The Company intends to take the actions necessary to regain compliance with the minimum bid price requirement within the period granted by the Panel. The Company’s common stock will continue to trade on the Nasdaq Capital Market during this period, subject to the Company’s compliance with the Panel’s decision and other applicable Nasdaq continued listing requirements.
“We are pleased to have completed the transfer to the Nasdaq Capital Market and appreciate the Panel providing the Company additional time to demonstrate compliance with the minimum bid price requirement,” said Scott Dam, Chief Financial Officer of Liminatus Pharma. “Maintaining our Nasdaq listing remains an important priority as we continue executing on our corporate and clinical development strategy.”
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The Company’s development portfolio includes IBA101, a humanized anti-CD47 monoclonal antibody being developed as a next-generation immune-modulating cancer therapy, together with additional therapeutic assets acquired through the Company’s strategic transactions.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, among other things, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing and effectiveness of actions taken to regain compliance, the Company’s continued listing on the Nasdaq Capital Market, and the Company’s corporate and clinical development plans. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no assurance that the Company will regain compliance with the minimum bid price requirement within the period granted by the Panel or maintain compliance with other applicable Nasdaq listing requirements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.
For more information, please contact:
Chris Kim, Chief Executive Officer
chris@liminatus.com
